Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Oct 06, 2018
- Analysis of data to date shows Translarna Preserved Ambulation for up to 5 Years Compared to Natural History - SOUTH PLAINFIELD, N.J. , Oct. 6, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced preliminary data from the first international drug registry for Duchenne
Additional Formats
Oct 03, 2018
- Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones - - SUNFISH Part 1 study demonstrated a 3.1-point increase in motor function as measured by MFM32 - - Pivotal portion of SUNFISH Part 2 study in Type 2 & 3 patients has completed enrollment - SOUTH
Additional Formats
Sep 28, 2018
SOUTH PLAINFIELD, N.J. , Sept. 28, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.
Additional Formats
Sep 25, 2018
SOUTH PLAINFIELD, N.J. , Sept. 25, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, October 9 th at 2:00 p.m. EST . The presentation will be webcast live on the Events and
Additional Formats
Sep 13, 2018

SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27 th at 1:30 p.m. EST . The presentation will be webcast live on the Events and

Additional Formats
Sep 07, 2018

- Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community - SOUTH PLAINFIELD, N.J. , Sept. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's 2018 global STRIVE Awards (Strategies to Realize

Additional Formats
Aug 24, 2018

SOUTH PLAINFIELD, N.J. , Aug. 24, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 22 , 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees.

Additional Formats
Aug 23, 2018

SOUTH PLAINFIELD, N.J. , Aug. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that it has successfully completed the acquisition of Agilis Biotherapeutics, Inc. , a private biotechnology company focused on the advancement of innovative gene therapy programs for rare

Additional Formats
Aug 10, 2018

SOUTH PLAINFIELD, N.J. , Aug. 10, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 6 , 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.

Additional Formats
Aug 07, 2018

Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children as young as 2 years of age Compelling data from FIREFISH study SOUTH PLAINFIELD, N.J. , Aug.

Additional Formats